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Commentary  
Implications for practice and research  
 
• Probiotics may be considered for children and adults with Cystic Fibrosis (CF) 
and might have some limited health benefits. 
• Further research is required on the effects of varying duration, dose and type 
of probiotics on children and adults with CF. 
 
Context 
 
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (1) and 
affects an estimated 70,000 adults and children around the world (2). The CFTR 
impairment causes gut ecosystem imbalance (3). It has been suggested that 
probiotics can help with restoring gut microbiota in patients with CF (4). This review 
aimed to summarize the current evidence on the efficacy and safety of probiotics for 
improving health outcomes in children and adults with CF (5). 
 
Methods 
 
This protocol registered systematic review carried out a comprehensive literature 
search of multiple databases (from database inception to 20 January 2020). Only 
randomised controlled trials [RCTs] which compared the effectiveness of any oral 
probiotic formulation compared to any other probiotic formulation, placebo or no 
treatment control in adults and children with CF were included.  Two reviewers 
carried out the screening process, data extraction and quality assessment 
(Cochrane collaboration criteria and GRADE) independently. An appropriate 
synthesis was carried out using a meta-analysis and a range of predefined and 
justified post-hoc subgroup analyses exploring age, dose, duration of washout and 
probiotic type for all primary and secondary outcomes where appropriate.   
 
 
 
 
Findings 
 
The evidence base for all outcomes were judged to be of low quality, in that the true 
effect might be substantially different from the effect reported within this review. The 
two main reasons for this uncertainty were selective reporting and the majority of 
studies only included children. The use of probiotics significantly reduced faecal 
calprotectin (intestinal inflammation marker) compared to placebo (-47.4 Bg/g, 95% 
CI:-93.28 to -1.54). There was a clinical and near statistically significant reduction in 
the number of pulmonary exacerbations comparing probiotics against a placebo after 
12 months (0.32 episodes per participant lower, 95% CI:-0.68 to +0.03). There was 
no strong evidence that probiotics improve weight, lung function and hospitalisations 
compared to placebo. There was limited evidence and inconclusive findings on the 
moderating effects of age, dose, duration of washout and probiotic type on the 
effectiveness of probiotics in children and adults with CF. There were four adverse 
events reported in the probiotic group, two RCTs reported a single event each of 
vomiting, one RCT of single event of diarrhoea, and one RCT was terminated due to 
one severe adverse event of urticaria. There were no adverse events reported in the 
control group. 
 
Commentary  
 
Using the Amstar2 Tool it was judged that the review provides an accurate and 
comprehensive summary of the results of the available studies that address the 
question of interest. However, these findings should be viewed with some caution 
due to the limited and low-quality evidence used for all outcomes, in particular when 
applying these findings to adults with CF as the majority of studies used children 
only.  
 
Nevertheless, due to the low level of reported adverse events and the reduction in 
faecal calprotectin (intestinal inflammation marker) and possible clinically significant 
reduction in the number of pulmonary exacerbations, probiotics may be considered 
for children and adults with CF. Although it is important to ensure these factors of 
adverse events, possible cost implications and the low confidence in effectiveness of 
probiotics are taken into consideration on an individual basis. 
 
There is still substantial uncertainty around the use of probiotics in children and 
adults with CF, particularly with regard to duration of use, dose and type of probiotic 
to be used. Furthermore, the effects on growth measures, hospital admissions, lung 
function and intestinal microbiota are still unclear. Multiple large multi-centred RCTs 
directly comparing these moderator variables and outcomes over at least a12-month 
period are required. Where appropriate a subset analysis for age should be 
undertaken. Further research is required before any definitive recommendations can 
be made for children and adults with CF. 
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